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Abstract
Background. Elderly patients with end-stage renal disease
and severe extra-renal comorbidity have a poor prognosis
on renal replacement therapy (RRT) and may opt to be
managed conservatively (CM). Information on the survival
of patients on this mode of therapy is limited.
Methods. We studied survival in a large cohort of CM pa-
tients in comparison to patients who received RRT.
Results. Over an 18-year period, we studied 844 patients,
689 (82%) of whom had been treated by RRT and 155
(18%) were CM. CM patients were older and a greater pro-
portion had high comorbidity. Median survival from entry
into stage 5 chronic kidney disease was less in CM than in
RRT (21.2 vs 67.1 months: P < 0.001). However, in patients
aged >75 years when corrected for age, high comorbidity
and diabetes, the survival advantage from RRT was ~4
months, which was not statistically significant. Increasing
age, the presence of high comorbidity and the presence of
diabetes were independent determinants of poorer survival
in RRT patients. In CM patients, however, age >75 years
and female gender independently predicted better survival.
Conclusions. In patients aged >75 years with high extra-
renal comorbidity, the survival advantage conferred by
RRT over CM is likely to be small. Age >75 years and fe-
male gender predicted better survival in CM patients. The
reasons for this are unclear.
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Introduction
Twenty-five years ago, a landmark publication drew atten-
tion to the rationing of access to renal replacement therapy
(RRT) in the UK [1]. In 1981, only 26.7 new patients per
million population (pmp) had been accepted into RRT pro-
grammes in the UK, in contrast to 42.3 pmp in France and
>60 pmp in the USA. Rationing was most striking in those
aged ≥45 years. Following these revelations, there was a
welcome liberalization of access to RRT, fuelling a dramat-
ic increase in acceptance rates, mirroring those across the
developed world. In the early years of the new millennium,
the incidence rates in the UK, like those in Northern Eur-
ope, stabilized at ~110 pmp, though far below those in the
USA currently at 361 pmp [2–4]. As a result, RRT popula-
tions throughout the developed world have expanded rap-
idly, the fastest growth occurring in the elderly, many of
whom are dependent, and frail.
The benefits of dialysis for elderly, dependent patients
with end-stage renal disease (ESRD), who often have mul-
tiple extra-renal comorbidities, have been questioned. The
prospects for rehabilitation in such patents tend to be slim,
and prognosis is often poor [5,6]. Dialysis in such circum-
stances can pose huge additional burdens for patients and
their carers. The practice of withholding dialysis in such
circumstances has been common [7–9]. In recent years,
the concept of the conservative management programme
has gained sway in an attempt to provide a comprehensive
package of care to patients who have chosen to forego dia-
lysis. Conservative management of ESRD involves a shift
from efforts to prolong life to those which focus on care,
quality of life and symptom control. Control of fluid and
electrolyte balance, anaemia management by use of
erythropoietin if need be, the provision of appropriate
end-of-life care and ongoing support for the patient and
family/carers are important aspects [10]. The concept has
been embodied as a switching focus from curing to caring,
though the notion of cure in the context of ESRD may be
stretching the point [11].
It is important to distinguish this rational and appropriate
use of therapies from the rationing approach referred to
above. Rationing in this context refers to the limiting of ac-
cess to expensive medical interventions in order to control
the use of resources. A rational or appropriate approach re-
fers to foregoing therapies in circumstances in which their
use is likely to be futile or detrimental to patient well-being.
A number of studies have described the outcome of
conservative kidney management [10,12–17]. In the com-
parative studies, dialysis for elderly patients with high co-
morbidity did not confer a significant survival advantage
over conservative management [10,12], at least in terms of
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hospital-free days [13]. In all these studies, the numbers
of patients treated by conservative kidney management
were small and follow-up relatively short. We studied a
large series of conservatively managed patients and com-
pared survival to those of a contemporaneous group of
RRT patients. We also studied the predictors of survival
in both groups.
Materials and methods
Patients
We reviewed the computerized records of all patients who had attended
our nephrology clinics with progressive chronic kidney disease (CKD).
We selected for further study all patients who had progressed as far as
stage 5 CKD based on eGFR estimated by MDRD-4 equation. This
was over an 18-year period to August 2008. To meet this criterion, each
patient had:
(1) At least one value of eGFR in the range 10–15 mL/min/1.73 m2
(2) All subsequent recorded values of eGFR <15 mL/min/1.73 m2
We examined detailed computerized records and the case notes for all
patients included in the study.
Survival in all patients was calculated from the date of the first re-
corded value in stage 5 CKD as outlined above. Patients who presented
in advanced stage 5 CKD (eGFR <10) were not included since the un-
availability of the date at which they reached stage 5 CKD made it im-
possible to estimate survival time from entry to stage 5.
Patients were categorized into RRT patients or conservatively managed
patients. Patients were designated as RRT patients if they:
(i) Subsequently commenced on dialysis either haemodialysis (HD) or
peritoneal dialysis (PD)—OR
(ii) Subsequently underwent pre-emptive transplantation—OR
(iii) Had made a decision to commence dialysis and had begun prepara-
tions for this, often involving the creation of an A-V fistula, but had
died before dialysis initiation.
Patients were designated as conservatively managed if they had made a
decision to forego dialysis, should their kidney failure continue to progress.
Modality choice
We aimed to offer patients a free choice of modality constrained only by
clinical and social imperatives. After the diagnosis of progressive CKD,
patients were referred by the nephrologists to a liaison team, led by a se-
nior nurse and a renal counsellor. This referral usually took place when
the patient had stage 4 CKD—but for a minority of patients this was
sometimes later. The role of the team included assessment, education,
counselling and support of the patient and family/carer before, during
and after modality choice. This process included a number of interviews
with each patient and significant others and at least one visit to the pa-
tient’s home. After subsequent discussions within the multidisciplinary
team, treatment options were discussed with each patient and significant
others and an individualized treatment plan formulated. Some patients
with low comorbidity chose CM when the chances of survival could have
been higher on RRT. They were specifically counselled on the potential
benefits of RRT, but their final decision was respected.
Conservative management programme
Patients opting for conservative management were offered ongoing support
by the multidisciplinary team in liaison with community, primary care and
hospice services. Full medical treatment was continued, which included the
use of erythropoietin as appropriate to treat or prevent anaemia.
Dialysis programme
HD patients were treated exclusively using high-flux membranes, pre-
dominantly polysulphone. Around 40% of patients were treated by online
haemodiafiltration (HDF). Bicarbonate was used exclusively as the buf-
fer, and ultrapure water was standard. Target total two-pool Kt/V urea
(Kt/VTotal) was 1.2 per session for thrice-weekly HD and HDF. PD pa-
tients were treated by continuous ambulatory peritoneal dialysis (CAPD)
or automated peritoneal dialysis. Disconnect systems were used exclu-
sively for CAPD. Minimum weekly Kt/VTotal target for both PD modes
was 2.0.
Data collected
The following information was obtained on all study patients from con-
temporaneous case notes and computer records:
(i) Date of entry into stage 5 CKD—defined as the date of the first
value of eGFR in the range 10–15 mL/min/1.73 m2.
(ii) Age—at entry into stage 5 CKD [see (i)]
(iii) Gender
(iv) Ethnicity—defined as white/non-white
(v) Presence of diabetes mellitus
(vi) The presence and severity of extra-renal comorbidity. Patients were
scored on the number and severity of the following conditions: car-
diac disease, peripheral vascular disease, cerebrovascular disease
and respiratory disease. The severity of these diseases was scored
as 0 = none, 1 = minimal, 2 = mild, 3 = moderate and 4 = advanced.
Cancer was also graded (1–4) according to its activity and nature
(medium-term survival). Cirrhosis was scored as a 4. Scores were
summed to form a combined comorbidity score [5]. A score of >4
was graded as ‘high’ and a score ≤4 was deemed as ‘low’.
(vii) Serum creatinine level and eGFR (calculated by the MDRD-4 equa-
tion), at the time of entry into stage 5 CKD [see (i)]
(viii) Date of death
Statistical analysis
Groups were compared, using unpaired t-tests and chi-square tests as ap-
propriate, with respect to age, gender ratio, ethnicity (white vs non-white),
the proportion with diabetes mellitus, comorbidity severity score and
eGFR on entry into stage 5 CKD. The Kaplan–Meier method was used
to compare the survival time between different groups. Differences were
assessed using the log-rank test. We used Cox proportional hazards model
to determine the predictors of survival. We used SPSS version 18 for all
statistical analyses.
Results
The total number of patients selected for study was 844,
689 (82%) of whom had been treated by RRT and 155
(18%) had been managed conservatively. The RRT group
included 18 patients (2.6% of the RRT group) in whom
dialysis had been planned, but died before dialysis initi-
ation. Using intention-to-treat analysis, these 18 patients
were included in all analyses. Patients who received con-
servative treatment were significantly older than those trea-
ted by RRT, and a much greater proportion of them had
high comorbidity (Table 1). RRT and conservatively man-
aged patients did not differ with respect to the distribution
of gender or ethnicity (white vs non-white), nor with re-
spect to the prevalence of diabetes. Estimated GFR at
the onset of the study period was also similar in RRT
and conservatively managed groups (Table 1). Patients
with severe comorbidity started dialysis at a significantly
higher mean eGFR compared to those with low comorbid-
ity (8.71, SD 2.58 vs 8.03, SD 2.54; P = 0.017).
Of the 155 patients in the CM group, 29 (18.7%) were
surviving at last analysis. Of the remaining 126 patients,
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57 (45.2%) died with a last recorded eGFR <8.22 mL/min/
1.73 m2 (median eGFR at start of dialysis in elderly pa-
tients) and 69 (54.8%) had last recorded eGFR higher than
this. However, it is not possible to conclude that renal fail-
ure did not contribute to death in the latter group or even
that at least some of these patients would not already have
started dialysis had they chosen this option.
Considering the whole group of 844 patients, median
survival in Kaplan–Meier analysis was far superior in
RRT patients than in those conservatively managed (67.1
vs 21.2 months: P < 0.001: Figure 1). Median survival was
also greater in those aged ≤75 years than in older patients
(67.0 vs 28.5 months: P < 0.001), in those without high
comorbidity compared to those with comorbidity (68.4
vs 25.1 months: P < 0.001) and in those without diabetes
than in those with diabetes (63.9 vs 44.7 months:
P < 0.001). Gender and ethnicity did not predictably influ-
ence survival. In the RRT group, there was improved me-
dian survival in patients aged <75 years (69.6 vs
33.0 months: P < 0.001), in the absence of high comorbid-
ity (72.5 vs 33.0 months: P < 0.001) and in non-diabetics
(74.4 vs 52.8 months: P < 0.001). Gender and ethnicity
again did not influence survival. In contrast, in the conser-
vatively managed group, patients >75 years had improved
median survival compared with younger patients (25.1 vs
15.5 months: P = 0.001), as did non-diabetics (24.4 vs
18.1 months: P = 0.011). Although median survival was
a little higher in patients without high comorbidity in this
group (26.0 vs 17.4 months), the difference was not statis-
tically significant (P = 0.124). Women also had a slightly
higher median survival than men (24.0 vs 19.5 months:
P = 0.084). There were no ethnic differences.
Considering all patients aged >75 years (Table 2 and Fig-
ure 2), those without high comorbidity had better survival
when treated by RRT rather than by conservative means
(36.8 vs 29.4 months: P = 0.03). However, patients in this
age group with high comorbidity, treatment by RRTwas as-
sociated with a smaller increase in median survival, of
around 5 months, which was not statistically significant
(Table 2 and Figure 2). Even within this elderly group, CM
patients were significantly older than RRT patients (81.8 vs
79.3 years; P < 0.001). When all patients who reached stage
5 CKD aged >75 years were analysed in a Cox proportional
hazards model, after correction for age, diabetes, comorbid-
ity, gender and ethnicity, RRT did not confer a significant
survival advantage (Table 3 and Figure 3).
In addition to the differences in age (81.8 ± 3.9 vs
68.4 ± 5.1 years), patients aged >75 years in the conser@-
vatively managed group were less likely to have diabetes
than younger patients and more likely to be white (Table 4).
There were no significant differences between those >75
years and younger patients with respect to gender distribu-
tion, the prevalence of high comorbidity and mean eGFR at
the start of the study.
In a Cox proportional hazards model, the significant
predictors of mortality in RRT patients were age—each
decade increasing mortality risk by >30%, the presence
of high comorbidity—incurring over twice the risk com-
pared to less comorbid patients and the presence of dia-
betes—associated with a 60% increased risk compared to
non-diabetic patients (Table 5). The findings were similar
if a dichotomized age covariate (≤75 and >75 years) was
substituted for the continuous age covariate in the model,
though the model's predictive power was slightly less
 RRT
Conservative      
Fig. 1. Kaplan–Meier survival curves from entry into stage 5 CKD for
patients treated by RRT (n = 689) and by conservative kidney
management (n = 155).
Table 1. Demographic and clinical details of patients treated by dialysis
and conservative kidney management
Conservative Dialysis P-value
Number 155 (18%) 689 (82%)
Age at stage 5 (years) 77.5 ± 7.6 58.5 ± 15.0 <0.001
% >75 years 68.4 11.2 <0.001
% Male 59.4 66.6 NS
% Non-white 14.2 15.7 NS
% Diabetes 35.5 34.3 NS
% High comorbidity 49.7 17.3 <0.001
eGFR at stage 5
(mL/min/1.73 m2)
13.2 ± 1.4 13.2 ± 1.4 NS
Table 2. Median survival by Kaplan–Meier analysis of patients aged >75 treated by conservative means or by dialysis, stratified by comorbidity group
Number Median SE
95% CI
P-valueLower bound Upper bound
Low comorbidity Dialysis 60 36.8 8.4 20.4 53.2 0.03
Conservative 52 29.4 3.7 22.2 36.6
Severe comorbidity Dialysis 17 25.8 4.4 17.3 34.4 0.83
Conservative 54 20.4 2.4 15.7 25.2
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(model not shown). Applying the same model in conserva-
tively managed patients produced differing results. The
significant predictors of mortality were age—mortality
being more than double in those aged <75 years compared
to older patients and gender—women having a 35% re-
duced risk compared to men (Table 6). Presence of high co-
morbidity and diabetes both conferred higher risk—though
this did not reach statistical significance. The better survival
of conservatively managed patients aged >75 yeas, adjusted
for gender, ethnicity, the presence of diabetes, the presence
of high comorbidity and eGFR at the start of the study, is
shown in Figure 4.
Discussion
For the vast majority of patients with ESRD, RRT provides
a huge survival advantage. However, in those >75 years of
age, this advantage may be restricted to those without high
comorbidity. We found that elderly patients with high co-
morbidity treated by dialysis had a median survival that
was only 5 months longer from entry into stage 5 CKD
than patients who had undergone conservative kidney
management—a small proportion of whom outlived all
those on RRT by a number of years (Figure 2). In fact,
when corrected for age, gender and comorbidity (Table 3),
patients aged >75 years did not gain a significant survival
advantage from RRT. This does not mean that dialysis will
not be of benefit for all elderly patients with ESRD. Clear-
ly an individualized approach is necessary. RRT is likely to
be beneficial in many patients especially those with low
comorbidity and in those with rapidly declining renal func-
tion. Conversely, CM may have a role in those patients
with high comorbidity and slowly declining renal function.
The predictors of survival in RRT and conservatively
managed patients were also markedly different. As might
be expected, in the RRT population, the independent pre-
dictors of increased mortality were increasing age, high
comorbidity and the presence of diabetes. In the conserva-
tively managed group, however, age >75 years and female
gender were both independent predictors of improved sur-
vival. The presence of high comorbidity and diabetes ap-
proached significance.
Why do older patients and females show better survival
in the CM group? In this study, older patients were less
likely to have diabetes, but the prevalence of high comor-
bidity was similar to that in younger patients (Table 4). In
any case, both these factors were controlled for in the Cox
model. We cannot exclude a role for gender difference in
the prevalence of primary renal diseases in this population,
Low comorbidity
p = 0.03 
High comorbidity
 p = 0.83 
 RRT
Conservative  RRT 
 Conservative 
Fig. 2. Comparison of Kaplan–Meier survival curves by modality (RRT vs conservative kidney management) in patients >75 years. The panel on the
left depicts the relationships in those with low comorbidity and that on the right in those with high comorbidity.
Table 3. Cox proportional hazards model for survival in patients aged >75. Increasing age, the presence of high comorbidity and male gender but not
the modality (CM or RRT) are significant predictors of mortality in this group of patients. Numbers in square brackets indicate the number of patients in
each category
Chi square = 30.91 (P < 0.001) P-value Hazard ratio
95.0% CI for HR
Lower Upper
Modality (CM [77] vs RRT [106]) 0.428 1.177 0.787 1.759
Age at stage 5 (years) 0.004 1.076 1.024 1.131
Comorbidity (high [71] vs low [112]) 0.002 1.823 1.255 2.650
Diabetes (diabetic [48] compared with non-diabetic [135]) 0.176 1.308 0.887 1.928
Gender (female [59] compared with male [124) 0.025 0.646 0.440 0.948
Ethnicity (non-white [12] compared with white [171]) 0.806 1.111 0.479 2.577
Survival of elderly patients with stage 5 CKD 1611
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for instance renovascular disease is more prevalent in men,
though the Cox model corrected for diabetes and presence
of severe comorbidity including vascular disease. The pro-
portion of non-whites was also significantly lower in older
patients (Table 4), but ethnicity was not an independent
predictor of survival. It may be that there are factors other
than those featuring in our survival model that are involved
in the choice of the conservative management option, and
which may be overrepresented in men and in younger pa-
tients, e.g. rate of decline of renal function, frailty, func-
tional status, social support and depression. Alternatively,
it may be that older patients can survive with less renal
function than younger patients and women with less than
men. Renal function declines progressively with increasing
age [18], perhaps associated with decreased metabolic de-
mand [19], but there is conflicting evidence for significant
gender differences in energy expenditure. Paul et al. found
that total energy expenditure, physical activity expenditure
and resting energy expenditure were significantly lower in
women [20]. Other authors have suggested that these dif-
ferences are abolished when corrected for body weight,
though the validity of such normalization is debated
[20,21]. Notwithstanding this, there are major gender dif-
ferences in body composition and insulin resistance that
may be relevant [21]. Females have also been shown to
have slightly higher iothalamate glomerular filtration rates
corrected for body surface area than males at all ages, at
least up to 60 years [22], but this is unlikely to be relevant
to elderly patients with ESRD.
Precisely how long patients survive on conservative kid-
ney management is difficult to gauge since the reference
point from which survival was measured has varied from
study to study. Some studies have attempted to match con-
servatively managed patients with a comparable dialysis
group whilst others report survival in the conservative
group alone. In a previous original study, we assessed sur-
vival from a ‘putative dialysis date’ obtained by matching
Cockcroft–Gault creatinine clearances in the conservative-
ly managed group with those in the relevant dialysis group
at dialysis initiation [10]. In that study, we found median
survivals of 6.3 months in conservatively managed patients
and 8.3 months in patients recommended for conservative
treatment but opting for dialysis. Carson et al. took a similar
approach, in ESRD patients aged >70 years, and found a
median survival of 13.9 months in the conservative group
and 37.8 months in RRT patients, though hospital-free sur-
vivalwas similar in both groups [13]. The groups were simi-
lar in terms of comorbidity, but median age was 8 years
greater in the conservative group. In octogenarians, median
Fig. 3. Cox proportional model survival curve of patients aged >75 years—CM vs RRT—adjusted for age, gender, ethnicity, the presence of diabetes
and the presence of high comorbidity. Median survival in RRT patients is better by <4 months, which is not statistically significant (P = 0.43).
Table 4. Comparison of demographic and clinical features in
conservatively managed patients aged >75 years and in those who
were younger
Age ≤75 Age >75 P-value
Number 49 (31.6%) 106 (68.4%)
Age at stage 5 (years) 68.4 ± 5.1 81.8 ± 3.9 <0.001
% Male 53.1 63.5 NS
% Non-white 26.5 8.5 0.005
% Diabetic 51.0 28.3 0.007
% High comorbidity 46.9 50.9 NS
eGFR at stage 5 (mL/min/1.73 m2) 13.0 ± 1.4 13.3 ± 1.4 NS
1612 S.M. Chandna et al.
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survival was 28.9 months in patients undergoing dialysis
and 8.9 months in those treated conservatively measured
from date of the decision not to perform dialysis (Cock-
croft–Gault creatinine clearance <10 mL/min in all cases)
[17]. The groups however, differed considerably with re-
spect to social isolation, late referral, Karnofsky perform-
ance score and diabetic status. Murtagh et al. found
survival from an eGFR of 15 mL/min to be similar at around
22 months in patients >75 years with high comorbidity in
the conservative and dialysed groups [12]. Ellam et al.
found that median patient survival on conservative manage-
ment from the time of f irst known CKD stage 5 was
21months [15].Wong found amedian survival of 1.95 years
in conservatively managed patients though some had not
reached stage 5 at entry into the study [14]. Our finding
of a median survival of 21 months for conservatively man-
aged patients following entry into stage 5 CKD is compat-
ible with much of the data outlined above.
There are a number of drawbacks in our study including
its retrospective nature and the absence of detail on patient
characteristics such as Karnofsky performance score and
frailty. This obliges caution in the interpretation of our re-
sults. These drawbacks however, are somewhat offset by
the size of the study, which is the largest currently available,
and the length of follow-up. We also used a non-standard
simplified comorbidity assessment derived from our previ-
ous work [5]. Our main purpose in this was to identify a
high-risk group using a score that reflected both the num-
ber and the severity of extra-renal comorbid conditions ra-
ther than just a count of affected organs. Assignment to the
high comorbidity cluster was a powerful predictor of mor-
tality in the dialysis group. We think, therefore, this ap-
proach was justif ied. It should also be noted that our
selection criteria effectively excluded most patients who
were referred late. Such patients represent >25% of new
starters on dialysis, and elderly, dependent patients are
over-represented in this group [5,23]. The lack of time to
counsel and plan in this setting may mean that patients
start on dialysis by default, perhaps inappropriately. This
is an important issue that is not addressed by this study.
Table 5. Cox proportional hazards model for survival in patients treated by dialysis. Increasing age, the presence of diabetes and the presence of high
comorbidity are significant predictors of mortality in this group of patients. Numbers in square brackets indicate the number of patients in each category
Chi square = 131 (P < 0.001) P-value Hazard ratio
95% CI for HR
Lower Upper
Gender (female [293] compared with male [551) 0.752 0.965 0.771 1.207
Ethnicity (non-white [132] compared with white [712]) 0.261 1.201 0.873 1.651
Diabetes (diabetic [291] compared with non-diabetic [553]) 0.000 1.604 1.293 1.990
Comorbidity (high [196] vs low [648]) <0.001 2.214 1.732 2.830
eGFR at stage 5 (mL/min/1.73 m2) 0.258 0.959 0.891 1.031
Age at stage 5 (years) <0.001 1.033 1.024 1.043
Table 6. Cox proportional hazards model for predictors of survival in patients treated by conservative management. Age ≤75 and male gender are
significantly associated with increased mortality in this group of patients
Chi square = 22 (P < 0.001) P-values Hazard ratio
95% CI for HR
Lower Upper
Gender (female [63] vs male [92]) 0.026 0.648 0.442 0.949
Ethnicity (non-white [22] vs white [133]) 0.824 1.062 0.627 1.799
Diabetic [55] vs non-diabetic [100] 0.094 1.409 0.943 2.105
Comorbidity (high [77] vs low [78]) 0.099 1.365 0.943 1.976
eGFR at stage 5 (mL/min/1.73 m2) 0.252 0.923 0.804 1.059
Age >75 (yes vs no) 0.009 0.574 0.379 0.869
Age > 75
Age ≤ 75
Fig. 4. Cox proportional model survival curve of conservatively managed
patients aged >75 years vs younger patients—adjusted for gender,
ethnicity, the presence of diabetes, the presence of high comorbidity
and eGFR at the start of the study. Survival of older patients is
significantly better than that of younger patients (P = 0.009).
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Whilst our results contribute to the information that can
guide patients in making treatment decisions, an individua-
lized approach to decision making is mandatory. Thus, an
elderly patient with high comorbidity and slow decline of
renal function is likely to benefit from conservative man-
agement; this may not be an appropriate recommendation
for someone with no comorbidity or rapidly declining
renal function. Survival figures can only provide general-
ized information, and each patient should be counselled in-
dividually on his or her chances of benef iting from
dialysis. Patients are free to change their treatment deci-
sions and these need to be respected when planning care.
Our study has contributed to our understanding of prog-
nosis in patients treated by conservative management. It
has also demonstrated a survival advantage for the elderly
(>75 years) and for women on this modality, though the
reasons for this are unclear. Conservative kidney manage-
ment is a valid treatment option in selected patients, and
our aversion to rationing should not dissuade us from ra-
tional treatment decisions. There is a dearth of prospective
work in this area. The little information we have on the
quality of life of patients on this pathway is reassuring
[16]. For many reasons, we are unlikely to acquire infor-
mation from randomized studies in this area [24]. High-
quality prospective observational studies of outcomes,
including quality of life, are urgently required.
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